New treatments and a vaccine for Valley Fever
Official title: SA-CCRC-Development of Therapeutics and Vaccines Against Coccidioidomycosis.
Funded at University of Texas San Antonio · NIH-11251788 · Data updated 2026-11-12
This program is working to create new medicines and a vaccine to help people who get Valley Fever or live where it spreads.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas San Antonio NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $1,357,000 |
| NIH project number | 5U19AI166761-05 |
| Project ID | NIH-11251788 on NIH RePORTER |
Who could benefit from this research
✓Could help
People diagnosed with Valley Fever, those with recurrent or severe infections, and people at high risk who live in endemic areas would be the most likely candidates for future trials.
✕Less likely to help
People without exposure to Coccidioides or with unrelated medical conditions are unlikely to benefit directly from this program in the short term.
What this research studies
Researchers at the San Antonio Coccidioidomycosis Collaborative Research Center are bringing together experts from multiple institutions to focus on Valley Fever. They will study the Coccidioides fungi in the lab, screen and develop antifungal drug candidates, and advance vaccine leads using preclinical models. The Center will track drug resistance and the changing geographic spread of the fungus, and build partnerships with industry to speed promising options toward human testing. Over time this work is meant to move lab discoveries into clinical trials for people in endemic areas.
Why it matters
Potential benefit: If successful, this work could produce new antifungal drugs and the first vaccine to prevent or better treat Valley Fever.
How similar studies have gone: Existing antifungal drugs can treat some cases but no human vaccine exists, and vaccine approaches have shown promise in animals but not yet in people.
Where this research is happening
-
University of Texas San Antonio
San Antonio, United States Active
Researchers
- Principal investigator: Hung, Chiung-Yu — University of Texas San Antonio
- Study coordinator: Hung, Chiung-Yu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.